Relmada Therapeutics (RLMD) Profit After Tax (2012 - 2026)
Relmada Therapeutics (RLMD) reported Profit After Tax of -$19.1 million for Q1 2026, down 8.5% year-over-year from -$20.8 million in Q1 2025, and up 4.11% quarter-over-quarter from -$19.9 million in Q4 2025.
Relmada Therapeutics (RLMD) Profit After Tax (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Profit After Tax data on file, last reported at -$19.1 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$19.1 million, down 8.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$58.9 million (up 22.23% YoY), and the FY2025 annual result was -$57.4 million, up 28.25% from the prior year.
- Profit After Tax grew to -$19.1 million in Q1 2026 per RLMD's latest filing, from -$19.9 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$9.9 million in Q2 2025 and troughed at -$39.9 million in Q2 2022.
- A 5-year average of -$24.3 million and a median of -$21.8 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax plunged 78.91% in 2022, then surged 53.55% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$37.9 million in 2022, then soared by 33.68% to -$25.2 million in 2023, then grew by 25.86% to -$18.7 million in 2024, then fell by 6.49% to -$19.9 million in 2025, then climbed by 4.11% to -$19.1 million in 2026.
- Business Quant data shows RLMD's Profit After Tax at -$19.1 million in Q1 2026, -$19.9 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -19.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -19.87 Mn |
| Sep 30, 2025 | -10.09 Mn |
| Jun 30, 2025 | -9.87 Mn |
| Mar 31, 2025 | -17.56 Mn |
| Dec 31, 2024 | -18.66 Mn |
| Sep 30, 2024 | -21.73 Mn |
| Jun 30, 2024 | -17.77 Mn |
| Mar 31, 2024 | -21.83 Mn |
| Dec 31, 2023 | -25.17 Mn |
| Sep 30, 2023 | -22.00 Mn |
| Jun 30, 2023 | -25.30 Mn |
| Mar 31, 2023 | -26.32 Mn |
| Dec 31, 2022 | -37.94 Mn |
| Sep 30, 2022 | -39.42 Mn |
| Jun 30, 2022 | -39.93 Mn |
| Mar 31, 2022 | -39.75 Mn |
| Dec 31, 2021 | -34.38 Mn |
| Sep 30, 2021 | -42.61 Mn |
| Jun 30, 2021 | -26.55 Mn |